Trials / Completed
CompletedNCT05084911
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)
A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,807 (actual)
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyramax | Pyronaridine-Artesunate(180/60mg) tablet for 3days. |
| DRUG | Placebo | Placebo tablet for 3days. |
Timeline
- Start date
- 2021-10-18
- Primary completion
- 2023-03-24
- Completion
- 2023-03-24
- First posted
- 2021-10-20
- Last updated
- 2023-06-18
Locations
66 sites across 6 countries: Argentina, Chile, Colombia, Poland, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT05084911. Inclusion in this directory is not an endorsement.